Regulatory Watch: Safety and Early Efficacy Study for Cardiac Pulsed Field Ablation System in Atrial Fibrillation

By Dr. Hatem Rabeh · Published February 13, 2026 · Updated March 16, 2026

Publication date context February 15, 2026. A not yet recruiting safety and initial efficacy study of a cardiac surgical pulsed field ablation system for the treatment of atrial fibrillation has been registered in the ClinicalTrials.gov database. The record identifies the device as a cardiac pulse field ablation device with a disposable cardiac surgical pulse field ablation electrode and lists two sponsors: Suzhou Sinus Medical Technologies Co., Ltd and Shanghai Zhongshan Hospital. The trial identifier is NCT07410962.

The registry notes the intervention as the Cardiac pulse field ablation device used with the disposable electrode to assess safety signals and early performance in patients with atrial fibrillation and related atrial arrhythmias. The entry confirms the status as not yet recruiting and does not provide enrollment dates in the public record.

What is this study?

The ClinicalTrials.gov record describes a safety and initial efficacy evaluation for a cardiac surgical pulsed field ablation system used to treat atrial fibrillation. The listing includes atrial fibrillation and fluttering in the conditions field and identifies not yet recruiting as the current status. The entry suggests a focus on early signal detection and device performance rather than long term outcomes.

Study design and device details

Interventions are listed as a Cardiac pulse field ablation device and a disposable cardiac surgical pulse field ablation electrode. Sponsors are Suzhou Sinus Medical Technologies Co., Ltd and Shanghai Zhongshan Hospital. The arrangement points to collaboration between a device developer and a hospital in China, signaling a joint development effort rather than a single institution study.

Regulatory notes imply standard safety monitoring and reporting of adverse events as part of the initial evaluation, with the intent to build early data to inform future regulatory decisions and potential expanded trials. The specific endpoints and statistical parameters are not disclosed in the record.

Who is conducting this study?

The sponsors named in the record indicate a coordinated effort between a Chinese device company and a major Shanghai hospital. This sort of collaboration is common in early phase device work where industry expertise and clinical experience combine to assess feasibility and preliminary safety in real world settings.

The partnership signals an intent to align device development with clinical needs in atrial arrhythmia management while maintaining oversight through hospital governance and sponsor oversight. Disclosure of funding and roles helps stakeholders assess potential biases and governance structures as data accumulate.

What device and procedure are involved?

The intervention is described as the Cardiac pulse field ablation device used with a disposable cardiac surgical pulse field ablation electrode. The description aligns with a surgically oriented approach aimed at creating precise lesions in target tissue while attempting to minimize collateral damage. The record does not detail procedural steps or operator training requirements.

As this is an early stage evaluation, the device performance will be observed for safety signals and initial efficacy indicators rather than definitive effectiveness outcomes. The entry frames the device as a potential option for atrial arrhythmia management pending further evidence.

What is the regulatory context?

The entry on ClinicalTrials.gov represents a safety and initial efficacy study for a cardiac pulsed field ablation system. The record indicates not yet recruiting and provides sponsor and device details but does not report results. This positioning places the study in the pre market evaluation phase under the MDR guidance for device innovation and safety assessment. Regulators will expect clear reporting of adverse events and device related performance metrics as enrollment begins.

What is the current status and next steps?

Not yet recruiting means no enrollment has begun in public records. The next steps would include site activation and participant enrollment if regulatory approvals are obtained and sites are prepared. The public record would be updated to reflect any progress, and sponsors may issue updates about recruitment timelines and pre enrollment activities. Stakeholders should watch for changes in the status field on ClinicalTrials.gov and for any communications from the sponsors.

Sponsor information and sources

Sponsors listed are Suzhou Sinus Medical Technologies Co., Ltd and Shanghai Zhongshan Hospital. The trial is registered under NCT07410962 on ClinicalTrials.gov. Link: https://clinicaltrials.gov/study/NCT07410962?term=medical+device

For quick reference see related sections linked above: What is this study and What device and procedure are involved.